French drugmaker Sanofi SA is partnering with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to $5.2 billion in milestone payments, the two companies said on January 7.

Pardes Biosciences Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a novel direct-acting, oral antiviral drug candidate designed to treat SARS-CoV-2 infections, announced the completion of its business combination with FS Development Corp. II, a special purpose acquisition company (SPAC) sponsored by Foresite Capital.


The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. 

The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.

In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.

GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.

Germany’s CureVac, which is gearing up to publish results of a key Covid-19 vaccine trial, said U.S. export restrictions on key materials are making it impossible to predict the company’s short-term supply ramp-up in Europe.

Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC), a particular purpose acquisition company sponsored by Patient Square Capital. 

After filing plans for an initial public offering earlier in April, U.K.-based Vaccitech raised $110.5 million in the company’s IPO and on April 30 announced the pricing of 6.5 million American Depositary Shares at $17 per share. 

Clarus Therapeutics Inc. and Blue Water Acquisition Corp. on April 27 announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company.